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OBJECTIVE — To evaluate the efﬁcacy and safety of taspoglutide (R1583/BIM51077), a
human once-weekly glucagon-like peptide-1 analog, in patients with type 2 diabetes inade-
quately controlled with metformin.
RESEARCH DESIGN AND METHODS — Type 2 diabetic (n  306) patients who
failed to obtain glycemic control (A1C 7–9.5%) despite 1,500 mg metformin daily were ran-
domly assigned to 8 weeks of double-blind subcutaneous treatment with placebo or taspo-
glutide, either 5, 10, or 20 mg once weekly or 10 or 20 mg once every 2 weeks, and followed
for 4 additional weeks. All patients received their previously established dose of metformin
throughout the study. Glycemic control was assessed by change in A1C (percent) from
baseline.
RESULTS — Signiﬁcantlygreater(P0.0001)reductionsinA1CfromameanSDbaseline
of 7.9  0.7% were observed in all taspoglutide groups compared with placebo after 8 weeks of
treatment: –1.0  0.1% (5 mg once weekly), –1.2  0.1% (10 mg once weekly), –1.2  0.1%
(20 mg once weekly), –0.9  0.1% (10 mg Q2W), and –1.0  0.1% (20 mg Q2W) vs. –0.2 
0.1%withplacebo.After8weeks,bodyweightlosswassigniﬁcantlygreaterinthe10mg(–2.1
0.3kg,P0.0035vs.placebo)and20mg(–2.80.3kg,P0.0001)once-weeklygroupsand
the20mgonceevery2weeks(–1.90.3kg,P0.0083)groupthanwithplacebo(–0.80.3
kg). The most common adverse event was dose-dependent, transient, mild-to-moderate nausea;
the incidence of hypoglycemia was very low.
CONCLUSIONS — Taspoglutide used in combination with metformin signiﬁcantly im-
proves fasting and postprandial glucose control and induces weight loss, with a favorable toler-
ability proﬁle.
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A
pproximately 50% of patients with
type 2 diabetes fail to achieve the
American Diabetes Association–
recommended target A1C level of 7% (1),
indicatingtheneedforadditionaltreatment
options.Anewclassofantidiabeticagentsis
the glucagon-like peptide-1 (GLP-1) recep-
tor agonists, which act through multiple
mechanisms (2), similar to the incretin
hormone GLP-1 (3–6). Taspoglutide
(R1583/BIM51077) is a human GLP-1
analog with a pharmacokinetic proﬁle
suitable for weekly subcutaneous admin-
istration, through two amino acid substi-
tutions in positions 8 and 35 with
aminoisobutyric acid and a sustained re-
lease formulation. Taspoglutide has 93%
homology with endogenous GLP-1 and
comparable in vitro potency. Taspo-
glutide is resistant to degradation by
dipeptidyl peptidase-4 and other pro-
teases, resulting in a 12-fold increase in
stability over the native GLP-1 when in-
cubated in rat serum (7). Taspoglutide
has been shown to enhance the rate of
glucose-induced insulin secretion from
isolated, cultured rat islets and the per-
fused ZDF rat pancreas (7,8). Further-
more, in vivo studies with taspoglutide in
Sprague-Dawley rats and diabetic db/db
mice have shown a dose-related enhance-
ment of glucose-dependent insulin re-
lease, which lowered blood glucose in the
db/db mouse model of type 2 diabetes (9).
Thus, the biological activity of taspo-
glutide is similar to that of native GLP-1,
with the added beneﬁt of a prolonged ac-
tion proﬁle.
The sustained release formulation of
taspoglutide showed a release proﬁle up
to 26 days in dogs, making it an attractive
candidate for human investigation (10).
Of note, in patients with type 2 diabetes
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gle 30-mg dose of the same 10% formu-
lation of taspoglutide improved fasting
and postprandial glucose for up to 14
days in nearly all subjects treated (11).
The aim of the current study was to eval-
uatetheefﬁcacy,safety,andtolerabilityof
a range of doses of taspoglutide, given ei-
ther once weekly or once every 2 weeks,
in patients with type 2 diabetes inade-
quately controlled with metformin alone.
RESEARCH DESIGN AND
METHODS— This was a random-
ized, double-blind, parallel group, place-
bo-controlled, multicenter, phase 2b
clinical study, consisting of a screening
(up to 3 weeks), a treatment (8 weeks),
and a follow-up period (4 weeks). The
study was conducted in accordance with
guidelines of all the institutional review
boards, with the principles of the Decla-
ration of Helsinki, and with the laws and
regulations of the countries where the re-
search was conducted.
The primary objectives of this study
weretodeterminetheefﬁcacy,safety,and
tolerability of multiple doses and regi-
mensoftaspoglutide,whenaddedtomet-
formin therapy. Secondary objectives
were to compare the effects of taspo-
glutide versus placebo on body weight
and additional parameters of glycemic
and lipid control.
Thestudypopulationcomprisedmen
and postmenopausal or surgically steril-
ized women with type 2 diabetes, treated
with a daily dose of metformin (1,500
mg/day) monotherapy for at least 3
months before screening. Key inclusion
criteria at screening were age 18–75
years, A1C between 7.0 and 9.5% (inclu-
sive), fasting plasma glucose (FPG) 126
mg/dl (7.0 mmol/l) and 240 mg/dl
(13.3mmol/l),BMI25and45kg/m
2,
and stable weight (10%) for at least 3
months before screening.
Key exclusion criteria were history of
type 1 diabetes; treatment with any anti-
hyperglycemic medication other than
metforminduringtheprior3months(ex-
ceptinsulinuseinacutesituationsordur-
ing surgery for up to 7 days); previous
exposure to GLP-1, GLP-1 analogs, or ex-
enatide; weight-lowering medications in
the prior 3 months; impaired liver or kid-
ney function, clinically signiﬁcant gastro-
intestinal disease, or uncontrolled
hypertension at screening; or a stroke or
myocardial infarction within 6 months
before screening.
Patients were randomly assigned by a
central randomization system (interactive
voice response system) to either placebo
once weekly or one of the following doses
and regimens of taspoglutide: 5 mg once
weekly; 10 mg once weekly; 20 mg once
weekly; 10 mg once every 2 weeks; or 20
mg once every 2 weeks. Patients were
asked to follow their prestudy diet and
exercise plan and metformin regimen
throughout the study. Patients reported
to the study site for weekly visits. At each
visit the lyophilized peptide was reconsti-
tuted at the study site with the diluent
(zinc chloride solution). Patients in the
placebogroupreceived0.9%NaCl.Study
medication was administered by person-
nel not involved with the preparation of
study drug to maintain the blinding and
injected subcutaneously in the abdomen
inadifferentsiteeachtime,accordingtoa
given scheme.
Patients measured their fasting blood
glucose levels using a glucometer (ACCU-
CHEK) while at home in the morning at
leastonceweeklyormorefrequentlyifthey
felt unwell or had any symptoms of hypo-
or hyperglycemia or if requested by local
guidelines. A subset of patients (n  118,
20 per group) consumed a mixed-meal
test with Ensure (350 kcal; 50 g carbohy-
drate, 13 g protein, and 11 g fat) at baseline
and after 8 weeks of treatment. Central lab-
oratories (Covance, Geneva, Switzerland;
Harrogate, U.K.; Indianapolis, IN) were
Figure 1—Patient ﬂow diagram. DB, database; QW, once weekly; Q2W, once every 2 weeks.
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including drug concentrations of
taspoglutide.
Study end points
The primary efﬁcacy end point was the
change from baseline in A1C (percent),
assessed1weekafter8consecutiveweeks
of treatment. Secondary end points in-
cluded the percentage of patients achiev-
ing the treatment goals of A1C 7% and
6.5% and the absolute changes from
baseline in FPG, body weight, fruc-
tosamine, C-peptide, fasting insulin, pro-
insulin,proinsulin-to-insulinmolarratio,
fasting glucagon, and lipid parameters.
Safety assessments included vital signs,
physical examination, clinical laboratory
tests,electrocardiogram,localtoleranceat
the injection site, anti-taspoglutide anti-
bodies, and adverse event reporting.
Statistical methods
Randomization was stratiﬁed based on
severity of disease (A1C 8% and
8%) and participation in the meal
test. The sample size of 264 patients (44
patients per group) was calculated to
provide 90% power to detect a 1% dif-
ference in the change of A1C from base-
line in the individual comparison of all
ﬁve active dose groups versus placebo,
assuming a common SD of 1.2%, two-
sided 0.05, and 20% dropout rate.
ANCOVA with ﬁxed-effect terms for re-
gion,treatment,andbaselineA1Cascovari-
ates was used to assess possible differences
in the changes in A1C among the treatment
groups.
The intent-to-treat population con-
sisted of all patients who were randomly
assigned, received at least one dose of
study medication, and had a baseline and
at least one postbaseline A1C assessment.
Missing data were handled using the last
observation carried forward method. The
safety population consisted of all patients
who received at least one dose of study
medication.
RESULTS
Baseline demographics and clinical
characteristics
Of 572 patients screened, 306 of them
were randomly assigned into six treat-
mentarms.Ofthe306randomlyassigned
patients, 297 received at least one dose of
study medication and were included in
thesafetydatabase(Fig.1).Therewereno
clinicallymeaningfuldifferencesinbaseline
demographic, anthropometric, or disease
characteristics among treatment groups
(Table 1). Patients were treated with com-
mon medications for a diabetic population
including ACE inhibitors, thiazide diuret-
ics, angiotensin receptor blockers, statins,
and -blockers (data not shown).
Pharmacokinetics
Thetaspoglutidemeanplasmaconcentra-
tions, based on the trough levels between
weeks 3 and 8, were 41.2, 77.5, and 96.6
pmol/l for the 5, 10, and 20 mg once-
weekly groups and 29.7 and 51.8 pmol/l in
Table 1—Baseline demographics, disease characteristics, and changes after the 8-week treatment
Once weekly Once every 2 weeks
Placebo 5 mg 10 mg 20 mg 10 mg 20 mg
n 49* 50* 49* 50* 50* 49*
Sex (female/male) 57/43 48/52 39/61 64/36 48/52 55/45
Age (years) 56  65 7  75 6  85 6  85 3  11 56  7
BMI (kg/m
2) 31.8  4.9 33.2  5.3 32.6  4.7 32.4  5.2 33.1  5.1 33.2  5.1
Duration of diabetes (years) 5  46  65  55  45  46  5
Metformin dose (mg/day) 2,019  63 1,897  51 1,888  53 1,998  57 2,011  68 1,934  56
Systolic blood pressure (mmHg) 129  13 127  13 128  14 131  14 132  13 132  13
Diastolic blood pressure (mmHg) 77  97 8  87 8  88 0  98 1  88 1  7
A1C (%) 8.0  0.1 7.9  0.1 7.9  0.1 7.8  0.1 8.0  0.1 7.9  0.1
	 0.2 	1.0 	1.2 	1.2 	0.9 	1.0
P 0.0001 0.0001 0.0001 0.0001 0.0001
Fructosamine (
mol/l) 310  6 310  6 300  6 292  6 309  6	 290  6
	 5  4 	44  4 	51  4 	48  4 	35  4 	40  4
P 0.0001 0.0001 0.0001 0.0001 0.0001
Fasting glucose (mg/dl) 173  5 187  5 175  5 164  5 175  5 171  5
	 14 	33 	45 	45 	22 	26
P 0.0002 0.0001 0.0001 0.13 0.02
Proinsulin-to-insulin ratio 0.590  0.032 0.579  0.032 0.594  0.032 0.550  0.032 0.606  0.031 0.613  0.032
 0.002 	0.079 	0.120 	0.166 	0.091 	0.055
P 0.0738 0.0076 0.0003 0.0372 0.2054
Lipid parameters
Total cholesterol (mg/dl) 211  6 201  6 195  6 194  6 196  6 200  6
 7 	8 	12 	9 	7 	12
LDL cholesterol (mg/dl) 127  5 117  5 116  5 113  5 114  5 114  5
 5 	3 	8 1 	0 	6
HDL cholesterol (mg/dl) 47  24 5  24 5  24 5  24 4  24 3  2
 0 	1 	2 	1 	10
Triglycerides (mg/dl) 224  27 220  27 188  28 199  27 220  27 256  27
 9 	22 	26 	48 	28 	27
Data are means  SD for baseline characteristics and mean  SEM for disease characteristics.
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group.
Glycemic control
After8weeksoftreatment,thereductions
in A1C from baseline were statistically
signiﬁcant compared with placebo in all
groups that received taspoglutide (P 
0.0001) (Fig. 2A, Table 1). Reductions in
A1C were apparent after 1 week of treat-
ment with taspoglutide, with the greatest
reductions observed in the 10 and 20 mg
once weekly dose groups at the end of
treatment. As expected, patients with
higher baseline A1C values (8.0%)
showed greater reductions in all treat-
ment groups, including placebo; the
change from baseline was –1.3%, –1.5%,
and –1.4% in the 5, 10, and 20 mg once-
weekly groups and –1.2% and –1.3% in
the 10 and 20 mg once every 2 weeks
group vs. –0.3% in the placebo group.
More than 44% reached a target A1C
7% in all active doses and regimens,
with 79 and 81% achieving this goal with
10 and 20 mg taspoglutide once weekly,
respectively, versus 17% with placebo
(Fig. 2B). Serum fructosamine signiﬁ-
cantly(P0.0001)decreasedinalltreat-
ment groups, consistent with the A1C
data (Table 1).
Reductions in FPG were apparent
within 1 week after initiation of treat-
ment. At the end of the treatment period,
weekly administration of taspoglutide re-
sultedinastatisticallysigniﬁcantdecrease
of FPG by 33 mg/dl (P  0.0002) with 5
mg and 45 mg/dl (P  0.0001) with both
10 and 20 mg doses versus a decrease of
14 mg/dl in the placebo group (Fig. 2C;
Table 1). When only four doses of taspo-
glutide were administered every 2 weeks
(i.e., 10 and 20 mg taspoglutide once ev-
ery 2 weeks), FPG rebounded during the
secondweekafterdrugadministration,as
shown in Fig. 2C. Nevertheless, the de-
crease in FPG (–26 mg/dl) in the 20 mg
onceevery2weeksgroupwasstatistically
signiﬁcant (Table 1).
-Cell function and glucagon
Mean fasting C-peptide concentrations
ranged from 0.8 to 1.0 nmol/l at baseline
andincreasedinalltreatmentarmsafter8
weeks of treatment. All treatment arms
showed an increase from baseline, with
the 20 mg once weekly group showing a
trend (P  0.069) and the 10 mg once
every 2 weeks group achieving statistical
signiﬁcance (P  0.009) after 8 weeks of
treatment.
The fasting proinsulin-to-insulin mo-
lar ratio ranged between 0.5 and 0.6 at
baseline and decreased in all treatment
arms (Table 1). A placebo-corrected, sta-
tistically signiﬁcant decline from baseline
couldbeshownforthe10mg(P0.008)
and 20 mg (P  0.0003) once-weekly
groupsaswellasforthe10mgonceevery
2 weeks (P  0.037) group. The mean
fasting glucagon concentration ranged
between6.9and7.8pg/mlatbaselineand
showedadecreaseinalltreatmentgroups
without reaching statistical signiﬁcance
(data not shown).
Lipid proﬁle
Baseline levels of fasting lipid parameters
and changes after 8 weeks are shown in
Table 1. All active treatment groups
showed a decline in triglycerides after the
treatment, compared with a slight in-
crease in the placebo control group. Pla-
cebo-corrected changes ranged from –32
Figure 2—Effects of taspoglutide and placebo on A1C. All taspoglutide doses were statistically signiﬁcant (P  0.0001) (A). Percentage of patients
achieving target A1C, *P  0.0001 vs. placebo (B); fasting plasma glucose (C); and body weight (D). Black, placebo; magenta, 5 mg once weekly;
green, 10 mg once weekly; yellow, 20 mg once weekly; purple, 10 mg once every 2 weeks; orange, 20 mg once every 2 weeks.
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maximumdecreaseof–58mg/dlinthe20
mg once weekly group.
Placebo-corrected changes in total
cholesterol levels varied from –15 to –20
mg/dl. Placebo-corrected changes in LDL
cholesterol levels ranged from –4 to –13
mg/dl,withnocleardoseresponse.There
wasatrendforaminimaldecreaseofHDL
cholesterol levels during this treatment
period.
Body weight
Body weight decreased progressively and
dose dependently throughout the 8-week
treatment period, with clinically mean-
ingful and statistically signiﬁcant reduc-
tions in the 10 mg once weekly (–2.1 
0.3 kg, P  0.0035), 20 mg once weekly
(–2.8  0.3 kg, P  0.0001), and 20 mg
once every 2 weeks (–1.9  0.3 kg, P 
0.0083) groups compared with the pla-
cebo group (–0.8  0.3 kg) (Fig. 2D).
Postprandial glucose and insulin
Aftertreatmentwithtaspoglutide,theme-
dian percent decrease from baseline in
plasma glucose 120 min after a mixed
meal was 21.6, 22.0, and 18% in the 5,
10, and 20 mg once-weekly groups and
12.0 and 5.5% in the 10 and 20 mg once
every 2 weeks groups vs. 10.5% in the
placebo group (complete postprandial
glucose data are shown in supplementary
Table 1, available in an online appendix
at http://care.diabetesjournals.org/cgi/
content/full/dc08-1961/DC1). Further-
more, the median percent change in
plasma insulin levels at 120 min was
22.2, 28.5, and 44.9% in the 5, 10,
and 20 mg once-weekly groups and –0.6
and–13%inthe10and20mgonceevery
2 weeks group vs. –15.3% in the placebo
group.
Safety and tolerability
Table2summarizesthemostfrequentad-
verseevents.Nauseaandvomitingtended
to occur during the ﬁrst day after study
drug administration, was associated with
peak plasma drug concentration, and re-
solved within 1 day. Subsequent admin-
istrations of taspoglutide were less likely
to induce nausea. The highest dose of ta-
spoglutide (20 mg once weekly) was as-
sociated with nausea and vomiting in 52
and 22% of patients, respectively.
Hypoglycemia occurred infrequently
(only seven events in six patients, two of
which were asymptomatic). No cases of
severe hypoglycemia occurred in the tas-
poglutide-treated patients. No cases of
pancreatitis were identiﬁed.
Six patients experienced serious ad-
verseevents,includingtwointheplacebo
group, all considered by the investigators
to be unrelated to the study drug. These
were perineal ﬁbroma and otitis media in
the placebo group and colonic polyp,
wrist fracture, coronary artery occlusion,
andunstableanginainthetreatedgroups.
The last two led to withdrawal from the
study. Eight patients discontinued pre-
maturelybecauseofadverseevents.These
were nausea (n  3, one patient in the 10
mg once weekly and two in the 20 mg
once weekly groups), vomiting (n  1),
hyperglycemia (n  1), hepatic cirrhosis
(n  1), unstable angina (n  1), and
coronary artery occlusion (n  1). He-
patic cirrhosis, unstable angina, and cor-
onaryarteryocclusionwerealldeemedby
the investigators to be unrelated to treat-
ment. Mild and moderate injection site
reactions were observed, which did not
resultintreatmentdiscontinuation.There
were no clinically relevant abnormalities
in scheduled electrocardiograms, vital
signs (including heart rate), or any labo-
ratory parameters after treatment with
taspoglutide.
CONCLUSIONS — This study dem-
onstrates that taspoglutide in patients
with type 2 diabetes inadequately con-
trolled with metformin produced statisti-
cally signiﬁcant and clinically meaningful
improvements in glycemic control in all
treatment groups, compared with pla-
cebo. This magnitude of improvement in
glycemic control observed with taspo-
glutide after 8 weeks (–1.1% decrease in
A1C from a baseline of 7.9  0.7%) com-
pares favorably with that seen with other
GLP-1 receptor agonists, such as ex-
enatide(12–14)andliraglutide(15).Both
fasting and postprandial glucose levels
were reduced by taspoglutide. Improve-
ment in glucose control during postpran-
dial as well as fasting periods is important
for reaching goal A1C (16). Our data in-
dicate that four of ﬁve patients treated
with 10 and 20 mg taspoglutide once
weeklyachievedthetreatmenttargetA1C
7% recommended by the American Di-
abetes Association (17).
Inaddition,intype2diabeticpatients
in whom metformin monotherapy had
failed, taspoglutide treatment produced
progressive, dose-dependent weight loss
with no evidence of a plateau after four or
eight injections at 8 weeks. The weight
loss is consistent with published clinical
trial data with other GLP-1 receptor ago-
nists (12–15). It is notable that the ob-
served weight loss occurred without any
speciﬁc diet or weight management
regimen.
The beneﬁcial effects of taspoglutide
on glycemic control and body weight loss
were accompanied by a meaningful im-
provement of the proinsulin-to-insulin
molar ratio. An elevation of this ratio is
predictive of subsequent development of
type 2 diabetes (18), and its decrease is
considered a sign of improved -cell
function (19). In addition, the observed
increase in postprandial insulin coupled
with reduced postprandial glucose after
taspoglutidetreatmentissuggestiveofen-
hanced glucose-dependent insulin secre-
tion. These results are consistent with the
mechanism of action of the class of incre-
tin-based treatments (6,12,20).
Type 2 diabetes is typically accom-
panied by cardiovascular and metabolic
disorders, including hypertension, dys-
lipidemia, and obesity (21). Despite re-
cent advances in therapy, diabetes is still
associated with excess cardiovascular
morbidity and mortality (21,22), medi-
Table 2—Most frequently reported adverse events
Once weekly
Once every 2
weeks
Placebo 5 mg 10 mg 20 mg 10 mg 20 mg
n 49* 50* 49* 50* 50* 49*
Nausea 3 (6) 11 (22) 12 (24) 26 (52) 16 (32) 20 (10)
Diarrhea 4 (8) 4 (8) 5 (10) 5 (10) 8 (16) 9 (18)
Vomiting 2 (4) 2 (4) 2 (4) 11 (22) 6 (12) 12 (24)
Headache 3 (6) 1 (2) 3 (6) 6 (12) 7 (14) 6 (12)
Decreased appetite — — 5 (10) 3 (6) 4 (8) 3 (6)
Dyspepsia — — 4 (8) 6 (12) 3 (6) 2 (4)
Abdominal distension — — 2 (4) 2 (4) 3 (6) 6 (12)
Dataaren(%).*Allpatientswhoreceivedatleastonedoseofstudydrugtreatment(n297)wereincluded
in the safety database.
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tors, including obesity. The salutary
effects of 8 weeks of taspoglutide treat-
ment on glycemic control, body weight,
and lipid proﬁle may improve the overall
metabolic and cardiovascular risk proﬁle
of type 2 diabetic patients. However, fur-
ther studies of longer duration, involving
a large number of patients, will be re-
quired to fully assess long-term cardio-
metabolic effects of taspoglutide.
Consistent with the available data on
other GLP-1 receptor agonists, the most
frequent adverse event seen with taspo-
glutide treatment was dose-dependent,
transient, mild-to-moderate nausea (12).
However, the majority of gastrointestinal
events were transient and resolved spon-
taneously without sequelae. Moreover, it
should be noted that the present study
was performed with ﬁxed doses. There is
evidence with both exenatide (23) and li-
raglutide (15) that gradual and progres-
sive dose escalation can reduce the
incidence of nausea (these adverse
events). To reduce the incidence of gas-
trointestinal events, an uptitration
scheme has been included in the ongoing
phase 3 program.
In summary, taspoglutide, given
weekly or every 2 weeks in combination
with metformin, resulted in signiﬁcant im-
provements in glycemic control and weight
loss after four to eight injections and was
well tolerated in the vast majority of pa-
tients. Thus, taspoglutide (10 and 20 mg
weekly) appears to offer the beneﬁts of a
weeklyGLP-1analog:potentglycemiccon-
trol, weight loss, and a low risk of
hypoglycemia.
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